Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis

• Published in: The oncologist (Dayton, Ohio) Ohio), 2009-01, Vol.14 (1), p.70-76
• Main Authors: Pinter, Matthias, Sieghart, Wolfgang, Graziadei, Ivo, Vogel, Wolfgang, Maieron, Andreas, Königsberg, Robert, Weissmann, Adalbert, Kornek, Gabriela, Plank, Christina, Peck‐Radosavljevic, Markus
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Benzenesulfonates - adverse effects; Benzenesulfonates - therapeutic use; Carcinoma, Hepatocellular - complications; Carcinoma, Hepatocellular - drug therapy; Female; Hepatocellular carcinoma; Humans; Liver cirrhosis; Liver Cirrhosis - complications; Liver Cirrhosis - drug therapy; Liver Neoplasms - complications; Liver Neoplasms - drug therapy; Male; Middle Aged; Multikinase inhibitors; Niacinamide - analogs & derivatives; Phenylurea Compounds; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Pyridines - adverse effects; Pyridines - therapeutic use; Sorafenib
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2008-0191

Background. Few data are available on the safety and efficacy of sorafenib in patients with multifocal hepatocellular carcinoma (HCC) and advanced liver cirrhosis. Methods. Between May 2006 and December 2007, we treated 59 patients (Child‐Pugh class A/B/C, 26/23/10) with unresectable HCC with sorafenib (daily target dose, 400 mg twice daily). Data were collected retrospectively. Survival curves were calculated via the Kaplan–Meier method. Results. One patient (Child‐Pugh class B) had a partial response, 14 patients (Child‐Pugh class A/B/C, 5/7/2) had stable disease, and 32 patients (Child‐Pugh class A/B/C, 15/11/6) had progressive disease; 12 patients were not evaluable because they had no follow‐up radiologic evaluation. In the intention‐to‐treat group, the median time to progression and overall survival (OS) time were 2.8 months (range, 1.4–6.5 months) and 6.5 months (range, 0.4–17.4 months), respectively. Well‐preserved liver function and lower Barcelona Clinic Liver Cancer stage were associated with a longer OS time on univariate analysis. There were four severe gastrointestinal bleedings (grade 4–5; Child‐Pugh class B/C, 2/2). Most drug‐related side effects were low grade and manageable irrespective of liver function. Conclusions. Sorafenib is effective and safe in patients with multifocal HCC and Child‐Pugh class A cirrhosis. Survival in Child‐Pugh class B patients is significantly less than in Child‐Pugh class A patients, warranting a prospective randomized trial with a placebo group. Child‐Pugh class C patients have a limited life expectancy despite sorafenib treatment because of their severe underlying disease and derive little benefit from sorafenib treatment. This study examines the efficacy and safety of sorafenib in the treatment of patients with unresectable HCC based on the severity of liver disease (Child‐Pugh class).